Results 21 to 30 of about 35,241 (222)

Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach.

ACS Medicinal Chemistry Letters, 2023
Fibroblast growth factor receptors (FGFRs) are transmembrane receptor tyrosine kinases that regulate multiple physiological processes. Aberrant activation of FGFR2 and FGFR3 has been linked to the pathogenesis of many tumor types, including ...
Minh-Hai Nguyen, H. Ye, Yao Xu, Lisa Truong, April Horsey, Peng Zhao, Evan D. Styduhar, M. Frascella, L. Leffet, Kelly Federowicz, E. Behshad, Anlai Wang, Ke Zhang, Michael R. Witten, Chao Qi, Ravi Jalluri, C. Lai, Onur Atasoylu, Jennifer J. Harris, Rod Hess, Luping Lin, Guofeng Zhang, M. Covington, S. Diamond, W. Yao, O. Vechorkin   +25 more
semanticscholar   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

Journal of Translational Medicine, 2021
Background Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied and there are no ...
Yue Wang, Tao Shi, Xuan Wang, Jinwei Hu, Lixia Yu, Qin Liu, Nandie Wu, Baorui Liu, Jia Wei   +8 more
doaj   +1 more source

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

Cancer Discovery, 2022
FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined ...
Qibiao Wu, Yuanli Zhen, Lei Shi, P. Vu, Patricia Greninger, Ramzi Adil, J. Merritt, Regina K. Egan, Meng-Ju Wu, Xunqin Yin, Cristina R. Ferrone, V. Deshpande, I. Baiev, C. Pinto, D. McLoughlin, C. Walmsley, James R. Stone, J. Gordan, A. Zhu, D. Juric, L. Goyal, C. Benes, N. Bardeesy   +22 more
semanticscholar   +1 more source

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma

The Journal of Pathology: Clinical Research, 2023
Intrahepatic cholangiocarcinoma harbours druggable genetic lesions including FGFR2 gene fusions. Reliable and accurate detection of these fusions is becoming a critical component of the molecular work‐up, but real‐world data on the performance of ...
O. Neumann, U. Lehmann, S. Bartels, N. Pfarr, T. Albrecht, Katharina Ilm, Jens Christmann, A. Volckmar, H. Goldschmid, M. Kirchner, M. Allgäuer, Maria Walker, H. Kreipe, A. Tannapfel, W. Weichert, P. Schirmacher, D. Kazdal, A. Stenzinger   +17 more
semanticscholar   +1 more source

Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

Journal of Clinical and Translational Hepatology, 2023
Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer for which effective therapeutic agents are lacking. Fibroblast growth factor receptor 2 (FGFR2) has become a promising therapeutic target in ICC; however, its ...
Yining Zou, Kun Zhu, Yanrui Pang, Jing-zhe Han, Xin K. Zhang, Zhengzeng Jiang, Yufeng Huang, W. Gu, Yuanyuan Ji   +8 more
semanticscholar   +1 more source

FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival. [PDF]

PLoS ONE, 2014
Aberrant kinase activation resulting from mutation, amplification, or translocation can drive growth and survival in a subset of human cancer. FGFR2 is amplified in breast and gastric cancer, and we report here the first characterization of FGFR2 gene ...
Anjili Mathur, Christopher Ware, Lenora Davis, Adi Gazdar, Bo-Sheng Pan, Bart Lutterbach   +5 more
doaj   +1 more source

Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization

Frontiers in Immunology, 2023
Introduction Lung metastasis occurs in parts of the bladder carcinoma (BC) patients but represents the highest severity and a poor outcome of the disease. The molecular mechanism underlying lung metastasis of BC is not fully understood. Fibroblast growth
Yuyang Zhao, Mingyang Li, Wenbo Wu, Wen-Fang Miao, HaiTao Liu   +4 more
semanticscholar   +1 more source

FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)

International Journal of Molecular Medicine, 2009
FGFR2 gene at human chromosome 10q26 encodes FGFR2b and FGFR2c isoforms functioning as FGF receptors with distinct expression domain and ligand specificity. FGFR2 plays oncogenic and anti-oncogenic roles in a context-dependent manner. Single nucleotide polymorphisms (SNPs) within intron 2 of FGFR2 gene are associated with breast cancer through allelic ...
Yuriko, Katoh, Masaru, Katoh
openaire   +3 more sources

Activating somatic FGFR2 mutations in breast cancer. [PDF]

PLoS ONE, 2013
It is known that FGFR2 gene variations confer a risk for breast cancer. FGFR2 and FGF10, the main ligand of FGFR2, are both overexpressed in 5-10% of breast tumors.
Nadine Reintjes, Yun Li, Alexandra Becker, Edyta Rohmann, Rita Schmutzler, Bernd Wollnik   +5 more
doaj   +1 more source